Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3903 ARTÍCULOS , VIENDO DEL 2626 AL 2640

Biological metals and metal-targeting compounds in major neurodegenerative diseases

Barnham KJ, Bush AI.

Chem Soc Rev. 2014 Oct 7;43(19):6727-49. doi: 10.1039/c4cs00138a. Epub 2014 Aug 7.

Paradoxical cellular effects and biological role of the multifaceted compound nordihydroguaiaretic acid

Hernández-Damián J, Andérica-Romero AC, Pedraza-Chaverri J.

Arch Pharm (Weinheim). 2014 Oct;347(10):685-97. doi: 10.1002/ardp.201400159. Epub 2014 Aug 6.

The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia

Escribano BM, Colín-González AL, Santamaría A, Túnez I.

CNS Neurol Disord Drug Targets. 2014;13(6):1096-119. doi: 10.2174/1871527313666140806160400.

The role of microglia in human disease: therapeutic tool or target?

Cartier N, Lewis CA, Zhang R, Rossi FM.

Acta Neuropathol. 2014 Sep;128(3):363-80. doi: 10.1007/s00401-014-1330-y. Epub 2014 Aug 9.

Benign hereditary chorea: a case report and brief review of inherited choreas

Kumar G, Dixon A.

Pediatr Neurol. 2014 Oct;51(4):532-6. doi: 10.1016/j.pediatrneurol.2014.06.001. Epub 2014 Jun 8.

Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease

Moulton CD, Hopkins CW, Bevan-Jones WR.

Mov Disord. 2014 Oct;29(12):1556-61. doi: 10.1002/mds.25980. Epub 2014 Aug 11.

Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington's disease

Ribeiro FM, Hamilton A, Doria JG, Guimaraes IM, Cregan SP, Ferguson SS.

Expert Opin Ther Targets. 2014 Nov;18(11):1293-304. doi: 10.1517/14728222.2014.948419. Epub 2014 Aug 14.

Metabolism in HD: still a relevant mechanism?

Duan W, Jiang M, Jin J.

Mov Disord. 2014 Sep 15;29(11):1366-74. doi: 10.1002/mds.25992. Epub 2014 Aug 13.

Advanced diffusion MRI fiber tracking in neurosurgical and neurodegenerative disorders and neuroanatomical studies: A review

Abhinav K, Yeh FC, Pathak S, Suski V, Lacomis D, Friedlander RM, Fernandez-Miranda JC.

Biochim Biophys Acta. 2014 Nov;1842(11):2286-2297. doi: 10.1016/j.bbadis.2014.08.002. Epub 2014 Aug 12.

HDL and cognition in neurodegenerative disorders

Hottman DA, Chernick D, Cheng S, Wang Z, Li L.

Neurobiol Dis. 2014 Dec;72 Pt A:22-36. doi: 10.1016/j.nbd.2014.07.015. Epub 2014 Aug 13.

Psychosis with Huntington's disease: role of antipsychotic medications

Ding J, Gadit AM.

BMJ Case Rep. 2014 Aug 19;2014:bcr2013202625. doi: 10.1136/bcr-2013-202625.

Proteostasis in striatal cells and selective neurodegeneration in Huntington's disease

Margulis J, Finkbeiner S.

Front Cell Neurosci. 2014 Aug 7;8:218. doi: 10.3389/fncel.2014.00218. eCollection 2014.

The ubiquitin proteasome system in glia and its role in neurodegenerative diseases

Jansen AH, Reits EA, Hol EM.

Front Mol Neurosci. 2014 Aug 8;7:73. doi: 10.3389/fnmol.2014.00073. eCollection 2014.

Genetic modifiers of Huntington's disease

Gusella JF, MacDonald ME, Lee JM.

Mov Disord. 2014 Sep 15;29(11):1359-65. doi: 10.1002/mds.26001. Epub 2014 Aug 25.

Targets for future clinical trials in Huntington's disease: what's in the pipeline?

Wild EJ, Tabrizi SJ.

Mov Disord. 2014 Sep 15;29(11):1434-45. doi: 10.1002/mds.26007. Epub 2014 Aug 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias